Of the two nodules with the BRAF V600E mutation, one was diagnosed as papillary thyroid carcinoma (PTC) and classified in the Bethesda IV category, while the second nodule (Bethesda III) is still awaiting surgery. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.